SEC Company Response from Dianthus Therapeutics, (DNTH) — Jun 18, 2018
Dianthus Therapeutics, Inc. /DE/ (DNTH) (CIK 0001690585)
Date: June 18, 2018 · CIK: 0001690585 · Accession: 0001193125-18-195382
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-225178
Letter
Re: Magenta Therapeutics, Inc.
June 18, 2018
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Registration Statement on Form S-1 (File No. 333-225178)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters (the “Underwriters”), hereby join in the request of Magenta Therapeutics, Inc. with respect to the effective time of the above-referenced Registration Statement so that it will become effective June 20, 2018, at 3:00 p.m. Eastern Time, or as soon thereafter as practicable.
In connection with this acceleration request and pursuant to Rule 460 under the Act, please be advised that, during the period from June 8, 2018 to the date of this letter, we have effected approximately the following distribution of copies of the preliminary prospectus, dated June 8, 2018, to underwriters, dealers, institutions, and others:
Requesting Party
Number of Copies
J.P. Morgan Securities LLC
1,580
Goldman Sachs & Co. LLC
Cowen and Company, LLC
Wedbush Securities Inc.
We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating Underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of Page Intentionally Left Blank]
Very truly yours,
J.P. MORGAN SECURITIES LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP June 18, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Magenta Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-225178) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters (the “Underwriters”), hereby join in the request of Magenta Therapeutics, Inc. with respect to the effective time of the above-referenced Registration Statement so that it will become effective June 20, 2018, at 3:00 p.m. Eastern Time, or as soon thereafter as practicable. In connection with this acceleration request and pursuant to Rule 460 under the Act, please be advised that, during the period from June 8, 2018 to the date of this letter, we have effected approximately the following distribution of copies of the preliminary prospectus, dated June 8, 2018, to underwriters, dealers, institutions, and others: Requesting Party Number of Copies J.P. Morgan Securities LLC 1,580 Goldman Sachs & Co. LLC 40 Cowen and Company, LLC 137 Wedbush Securities Inc. 145 We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating Underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Remainder of Page Intentionally Left Blank] Very truly yours, J.P. MORGAN SECURITIES LLC GOLDMAN SACHS & CO. LLC COWEN AND COMPANY, LLC on behalf of themselves and as representatives of the Underwriters J.P. MORGAN SECURITIES LLC By: /s/ David Ke Name: Title: David Ke Executive Director GOLDMAN SACHS & CO. LLC By: /s/ Raffael Fiumara Name: Title: Raffael Fiumara Vice President COWEN AND COMPANY, LLC By: /s/ Bill Follis Name: Title: Bill Follis Managing Director [Signature Page to Underwriters’ Acceleration Request Letter]